Intranasal corticosteroids are well known to be efficaciousin the treatment ofallergic rhinitis. Nasal irrigation with saline, including hyp ertonic saline, has long been recommended for the treatment of sinonasal disease, and it has been shown to have a positive effect on the physiology of the nasal mucosa. Until now, no study of the clinical efficacy of intranasal hyp ertonic Dead Sea saline as a monoth erapy for seasonal allergic rhinitis has been reported. We conducted a prospective, randomized, single-blind,placebo-controlled comparison ofintranasal hypertonic Dead Sea saline sp ray and intranasal aqueous triamcinolone spray in 15patients with seasonal allergic rhinitis. Results were based on a 7-day regimen. Based on Rhinoconj unctivitis Quality of Life Questionnaire scores, clinically andstatistically significant (p < O.0001) improvements were seen in both active-treatment groups; as expected, the corticosteroid spray was the more effective of the two treatments. No significant improvement occurred in the control group. Our preliminary results not only confirm the efficacy ofintranasal corticosteroid therapy in moderate-to-severe allergic rhinitis, they also suggest that the Dead Sea saline solution can be an effective alternative in mild-to-moderate allergic rhinitis, particularly with respect to nasal and eye symptoms. The hypertonicity ofthe Dead Sea solution may have apositive effect on the physiology ofthe nasal mucosa by improving mucociliary clearance. In addition, the dominant cation in the Dead Sea solution-magnesium-probably exerts anti-inflammato ry effects on the nasal mucosa and on the systemic immune response.
Introduction
Symptoms of seasonal allergic rhinitis are usually caused by tree, grass, and weed pollens. An important place to consider seasonal allerg ic rhinitis is Tulsa, Okla., which is located in the northeast region ofthe state and is known as "Green Country." The city lies at the threshold of two dist inct zones -a deciduous forest area and a grass lands . area-in which the population is exposed to a diversity of allergenic vegetation. I These two zones are popu lated by vegetation that accounts for 70% (127 of 181) of all allergenic species and by 79% (26 of 33) of the most allergenic species.I
The highest concentrations of airborne tree pollens are typically seen in the early spring. Genera inclu de Quercus (oak),Juniperus (cedar), and Ulmus (elm). Quercus releases the most abundant poll en during any season." Juniperus ashei (mountain cedar) pollen is carr ied upwind into the Tulsa area from southwest Okla homa and west Texas during the fall and through the winter.v'
In the late spring and early summer, polle ns are relea sed by other allerge nic trees , such as Juglans regia (walnut) and Carya illinoensis (pecan). Also, a number of grasses pollinate from late spr ing through the summer; among the most allergenic are Cynodon dactylon (bermuda) and Phleum pratense (timothy). Fall is typically the season for Ambrosia trifida (giant ragweed ), which is the second most abundant pollen in the Tulsa area ; pollination usually peaks in mid-September and ends in early October.
In addition to allergen avoidance, proven treatments for seasonal allergic rhinitis include intranasal cortic ostero ids, oral and topical HI receptor antagonists (antihistamines), intranasal saline solutions, and occasi onall y immunotherapy; recently, treatment with leukotriene receptor antagonists has also been suggested. The superior effects of intranasal corticosteroids in sinonasal diseases have been established with respect to symp tom resolution and quality of life.t" Intranasal corticosteroids also have a sign ificant effect on inflammatory mediators in allergic rhinitis .P-" In fact, when ENT-Ear, Nose & Throat Journal s July 2005 compared with oral antihistamines and with leukotriene receptor antagonists (with intranasal saline typically used as a control) for the treatment of seasonal allergic rhinitis, corticosteroids have been shown to be superior. 5 , 7, 9, II, 12 The effects of intranasal hypertonic saline solutions are less clear. Some studies have shown that they exert beneficial effects on nasal physiology, mucociliary clearance in particular, 15·18 and that they help relieve symptoms and improve quality of life in patients with sinonasal disease.":" Other studies, however, have shown that they have a negative effect on nasal physiology and no effect on symptoms of sinonasal disease.P'"
One such hypertonic saline solution is made from Dead Sea salts. The Dead Sea is the world's most saline lake body, and it contains proportionately more magnesium, calcium, bromine, and potassium and less sodium, sulfate, and carbonate than any ocean." Magnesium is the dominant cation, accounting for approximately 35% ofthe composition of Dead Sea salts. This chemical composition makes Dead Sea salt unlike any other sea salt in the world."
Treatment with Dead Sea salts has been shown to have positive effects on skin conditions such as psoriasis" and contact eczema." The magnesium ion is believed to be primarily responsible for these positive effects.t':" Also, it is well established that magnesium in its intravenous.l':" inhaled and nebulized.P:" and dietary >" forms plays a role in treating acute asthma, which is known to cause a reaction similar to an allergy.
A report from Italy revealed that intranasal hypertonic saline was beneficial in reducing the amount ofas-needed antihistamines in a pediatric population with seasonal allergic rhinitis. " Until now, no study has been published regarding the effects ofhypertonic saline as a monotherapy for seasonal allergic rhinitis . In this article, we describe what we believe is the first such preliminary study.
Patients and methods
Patient population. Our study population was originally made up of 21 patients who had presented to the family practice office ofone ofthe authors (J.B.H .) seeking treatment for symptoms of seasonal allergic rhinitis. In order to be eligible for this study, patients had to be at least 18 years of age, had to have experienced at least two of six symptoms (nasal stuffiness, watery/itchy eyes, rhinorrhea, sneezing, postnasal drainage, and itchy throat/cough) at presentation, and had to have had a positive skin puncture test for seasonal allergens . Exclusion criteria included the presence of chronic sinusitis, nasal polyposis, a deviated nasal septum or history of nasal septal perforation, and recent nasal or sinus surgery; the use of an antihistamine, cromolyn, decongestant, or a topical or systemic corticosteroid within the preceding 2 weeks or an immunotherapeutic agent within the preceding 2 years; pregnancy and/or lactation; and chronic conditions such as head and Volume 84, Number 7 neck cancer, human immunodeficiency virus-related nasal disease, cystic fibrosis, and renal, hepatic, pulmonary, and cardiovascular disease .
During the study, 6 of the 21 patients withdrew. Two patients withdrew because of adverse reactions, 2 did not return for the second of two scheduled visits, 1 was disqualified for antihistamine use during the study period, and I had stopped treatment prematurely. The final data analysis , therefore, was based on findings in the 15 patients-3 men and 12 women, aged 20 to 74 years (mean: 35.2 ± l6.05)-who completed both visits .
Written informed consent was obtained from all patients. The research protocol and the informed consent form were approved by the Institutional Review Board of Family Medical Care of Tulsa, Inc.
Study design. This randomized, single-blind, placebocontrolled study was conducted during 6 weeks of the spring allergy season in Tulsa, Okla. All patients were required to comply with the study protocol at two office visits . The treatment protocol was explained to them with both oral and written instructions.
Patients were randomized into 3 groups of 5 each to receive either intranasal hypertonic Dead Sea saline spray (2 sprays into each nostril 3 times daily), aqueous triamcinolone spray (110 ug into each nostril once daily) , or a placebo nasal saline spray (2 sprays into each nostril 3 times daily) for 7 days.
At the first visit, each patient underwent skin-prick allergen testing for tree pollen (American elm, post oak, and mountain cedar), grass pollen (bermuda and timothy), short ragweed pollen , andAlternaria mold extract. Patients also completed the standardized version ofthe Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), once at the first visit and again at the completion of treatment. The RQLQ is a reliable, validated instrument with strong discriminative properties.v -" The survey contains 28 questions regarding 7 domains: activities, sleep, practical problems, nasal symptoms, eye symptoms, other symptoms, and emotional status. For eachdomain, patients rate themselves as to how much their symptoms have affected them during the previous week on a scale of 0 (no effect) to 6 (great effect). on any RQLQ dom ain. Jun iper et ai, who developed the RQLQ , defined a clinically significant difference as "the sma llest difference in score in the domain of interest which patients perceive as beneficial and would mandate a change in management," and they provided evidence that this difference is 0.5. 40 Based on this interpr etation, the placebo in our study did lead to a clinic ally significant difference in three domains: sleep , eye symptoms, and emotional status . This finding supports the idea that although nasal saline is typically used as a control in studi es of al1ergic rhinitis, it is not a genuine placebo. Ratne r et al hav e suggested that oral nonsedative antihistamines have been shown to be no more effective than placebo aqueous nasal sprays in placebo-control1ed studies in which the active comparator was an intranasal corticosteroid, but they have been shown to be superior to placebo tablets when the active comp arator was anothe r oral antihistamine. II In light ofthe findings by Ratner et al and their belief that intranasal saline washes the nasal mucosa of al1ergens and mucus, we sugge st that the efficacy of intranasal saline might be equa l to that of oral HI receptor anta gonists for some pat ients with mild symptoms. Nasal salin e may indeed playa role in the treatment of al1ergic rhinitis when it is deli vered as a true irrigation agent ratherthan asjust a simpl e moisturizer. One Tulsa al1ergist , Jane Purser, MD, recommends nasal saline irrigation with a min imum of5 sprays in each nostril every mornin g, and she has observed some clinical1y significant improvements amon g her patients wit h chronic sinonasal diseas e (oral communication , Febru ary 200 I). We believe that nasal saline spray as a placebo is probably adequate for research purposes, but it does provide some actual clin ical benefit as an irrigant in some patients.
Dead Sea saline. The use of the intranasal hypertonic Dead Sea saline solution in our study resulted in some moderate but clinically and statistically significant improvement in posttreatment RQLQ scores. It was most effective in treating nasal symptoms. It was also significantly more effecti ve than the placebo in all 7 domains. We belie ve ours is the first stud y to demonstrate the poss ible efficacy of intranasal hypertonic Dead Sea saline solution in alleviating symptoms and impro ving overall quali ty oflife in patients with seasonal allergic rhinitis. Th e Dead Sea solution 's mechanism of action is unclear, but we can offer some possible explanations . Like the nasalsaline placebo, it may act as a mild irrigant and physi cally clear mucu s and inflamm atory cells . It may also have positi ve effects on the physiolo gy of the nasal mucosa and muco ciliary clearance. 15.16 Finally, in view ofits beneficial effect on eye symptoms, it may have global anti-inflammatory properties and affect the systemic immunologic response to allergic rhinitis.
Discussion
Corticosteroids. Our expected find ing that triamcinolone resulted in a statistically significant alleviation of severe symptoms and improvement in quality oflife is consistent with the large body of evidence that intranasal corticosteroids are not only efficacious but superior for the treatment of seasonal allergic rhinitis . 5 ,7.9, I I, 12 It is interesting that of the 7 RQLQ domains, intran asa l triamcinolone's greatest effect was on reducing eye symptoms (i.e., conjunctivitis). This suggests that allergic rhinitis is a disease ofsystemic immunologic response and that intranasal corticosteroids have a global effect rather than just a local effect.
Saline control. According to our anal ysis , nasal saline as the control preparation had no statistically significant effect 
Results
Following treatment, clinically and statistically significant improvem ents in mean composite RQLQ scores were seen in both the Dead Sea saline group and the corticosteroid group; no significant impro vement occurred in the control group (table) . The De ad Sea saline group experienced a significant reduction in the mean composite RQLQ score , which fel1 from 3.38 to 2.02 , a difference of 1.36 (p < 0.0001).
As expected, the corticosteroid group exper ienced the most marked overall impro vement, as its mean composite RQLQ score declined from 3.24 to 1.03, a difference of 2.21 (p < 0.0001).
In the control gro up, the mean composite RQLQ score was 2.60 pr ior to treatment and 2044 afterward, a difference of 0.16. The difference was not statistical1y significant (p = 0.6483). Likewise, there was no significant difference in any of the 7 domain scores pre-and posttreatment.
In both active-treatment groups , improvements were seen in all 7 individual dom ains. The greatest impro vements in the Dead Sea saline group involved nasal symptoms (from 3.83 to 2.17 , a difference ofl .66) and eye symptoms (from 3.00 to 2.04, a difference of 0.96). In the cort icosteroid group, the greatest impro vements involved eye symptoms (from 3.75 to 0.85, a difference of2.90) and nasal symptoms (from 3.65 to lAO, a differ ence of2.25).
Table. Mean composite RQLQ scores pre-and posttr eatm ent in the 3 groups
Magnesium. Regardin g the latte r expl anation , magnesium is the dominant cation in the Dead Sea saline solution, and it is reason able to postulate that magnesium exerts some effect on inflammatory cells or inflammatory mediators. Asthma is kno wn to be associated with incre ased amounts of eosino phi Is and has long been belie ved to cause a reaction similarto an allergy. Intravenous magnesium has been shown to be benefic ial in the treatment ofacute asthma," :" and nebulized magnesium in combination with albuterol was shown to exert beneficial effects in a pediatric population in an eme rgenc y department in Detroit." In another study, 36.8 % of asthma patients who were treated for 4 weeks at the Dead Sea itself wer e able to discontinue their medications; even tho se who continued inhalation treatment were able to reduce the frequ ency of their puffs by 43%. 34 Dietary magn esium has positive effects, as well. Researchers in the United Kingdom found that a dietary reg imen high in magnesium significantly improved lung function and lowered asthma symptom scores.":" The role of magnesium in lung function is prob ably twofold: (I) Magnesium relaxes bronchial smooth muscle and thereby dilates airways, and (2) it may exert some influence on inflammatory cells and their subsequent rele ase of inflammatory mediators.
Evidence of the positive effect that magnesium in Dead Sea salts has on som e skin disea ses was reported by Greiner and Die zel in Germany." Th ey administered water with a high conc entration ofmagnesium ions to mice with allergenic contact derm at itis that had been induc ed by l-chloro-2 , 4-dinitrobenzene (DN CB). Mice that were challenged by DNCB plus magnesium chloride experienced sign ificantly less inflamm ation than did mice that were challenged by DNCB alone and by DNCB plus sodium chloride. Greiner and Diezel confirmed these find ing s in 5 humans who had a known allerg y to nickel; magne sium chloride suppressed nickel sul fate-induced contact derm atitis, and sodium chloride did not." Another study from Germany by Ludwig et al revealed that high concentrations of magnesium ions inhibited the release of arachidonic acid (an important precursor of inflammatory mediators) and leukotriene B4 (a potent regulator in inflammatory reactions) in polymorphonuclear leukocytes ." Ludwi g et al concluded that high concentration s of magnesium inhibit eicosanoid metabolism dur ing the release of arachidonic acid by directly inhibiting the 5-lipoxygen ase enzym e.
Magnesium probably stabilizes eosinophils (which under certain conditions degranulate major basic protein) and mast cells (which deg ranulate histamine). It has been demonstrated that when magnesium levels in the blood decrease , eosinophil and histamine levels subs equently increase.v It has also been shown that magnesium inhibits eosinophils from undergoing exoc ytosis and degr anulation." All ergic rhinitis typ ically begins with the exposu re of IgE-bound mast cells to an allergen and progresses to subsequent mast Volume 84, Number 7 cell degranulation and histamine release .Throu gh a numb er ofmechanisms , this activity causes sy mptoms of sneezing, rhinorrhea , nasal and ocular itchiness, eye watering, and cough . Chemotactic factors presum ably modulate the influx of eosinophils, one of which is histamine. Magnesium administered intranasally via Dead Sea saline solution may inh ibit eosinophil release of majo r basic protein and mast cell release of histamine, the reb y inhibiting the local immune response and probably creating the anti-inflammatory effect of the systemic response.
Our data suggest that the use of intranasal hyp ertonic Dead Sea sali ne solution in a spray form res ults in a moderate reduction of symptoms and a moderate improv ement in overall qual ity of life in pat ients with seasonal allergic rhinitis, and that it is prob ably useful in patients with mild-to-moderate symptoms. Th e Dead Sea solution also app ears to be sign ificantly better tha n nasal saline placebo in reducing symptoms and improving quality of life , and it probably exerts antiinflammatory effects on the nasal mucosa and the systemic inflammatory response. Patients with moderate-to-severe symptoms should probably be treated with an intranasal corticost eroid, with or without a nas al wash with Dead Sea sal ine solution. It is possible that a different delivery system-namely irrigation-may enh ance the positive effects ofthe Dead Sea solution, and we hope that such a study can be undertaken.
In conclusion, it appears that the intr ana sal hypertonic Dead Sea sal ine solution is super ior to plain saline solution in the treatment of seasonal allergic rhinitis. However, in view of the small number of patients in our study, these results are only preliminary. Fortunately, several studies are under way to help confirm or refute our conclusion.
